UCB has agreed to pay $34 million to resolve claims it marketed Keppra, an epilepsy drug, to treat headaches and pain. The FDA approves neither use of the drug. UCB must also plead guilty to a
misdemeanor as part of its deal with the Justice Department.
Read the whole story at FiercePharma.com »
